Hypertension screening and treatment with angiotensin inhibitors. Saralasin and captopril.
The number of studies in the literature on diagnostic and therapeutic uses of angiotensin antagonists has been increasing geometrically. Nearly 1,000 publishsd items deal with saralasin alone, although neither saralasin nor captopril is yet approved for general use or widely available. Reports to date represent only a fraction of the eventual situations in which these agents are likely to help the researcher and clinician. Food and Drug Administration approval of both agents is pending, and both are expected to be available soon. Consequently, the practitioner will want to become familiar with their usefulness, especially to screen for secondary forms of hypertension and to treat moderate to severe primary or secondary hypertension.
D000804:Angiotensin II / Q000031:analogs & derivatives*; D000809:Angiotensins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D006977:Hypertension, Renal / Q000175:diagnosis*; D006978:Hypertension, Renovascular / Q000175:diagnosis* / Q000188:drug therapy; D011392:Proline / Q000031:analogs & derivatives*; D012083:Renin / Q000097:blood / Q000378:metabolism; D012504:Saralasin / Q000494:pharmacology / Q000627:therapeutic use
D000809:Angiotensins; D000804:Angiotensin II; D011392:Proline; D002216:Captopril; D012083:Renin; D012504:Saralasin